Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETCABio – Evaluation of Skin Tests in Biotherapy Allergies
2024-519812-15-00Phase 4Authorised
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Apr 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab, pembrolizumab, atezolizumab, durvalumab, obinutuzumab and 2 more in colorectal cancer (CRC), colorectal adenocarcinoma, follicular lymphoma (FL) and 13 more, sponsored by Centre Hospitalier Universitaire d'Angers. Planned start Apr 2025; status: authorised.
02
Drugs
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinomafollicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)pleural mesothelioma
Beyond the preview
Go deeper on 2024-519812-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519812-15-00.